ArticleMicrobiologyOpen2020
A construction strategy for a baculovirus-silkworm multigene expression system and its application for coexpression of type I and type II interferons.
Article in MicrobiologyOpen, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Identification of extracellular vesicle microRNAs as potential facilitators of interferon-alpha escape in Marek's disease virus infection.Frontiers in cellular and infection microbiology · 2026Article
- Optimized production and antiviral activity evaluation of recombinant chicken interferon-alpha using an improved Baculovirus expression system.Poultry science · 2025Article
- A SARS-CoV-2 Nanobody Displayed on the Surface of Human Ferritin with High Neutralization Activity.International journal of nanomedicine · 2024Article
- Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice.Process biochemistry (Barking, London, England) · 2023Article
- In vivo enzymatic digestion of HRV 3C protease cleavage sites-containing proteins produced in a silkworm-baculovirus expression system.Bioscience reports · 2022Article
- Optimization of a Lambda-RED Recombination Method for Rapid Gene Deletion in Human Cytomegalovirus.International journal of molecular sciences · 2021Article
- A construction strategy for a baculovirus-silkworm multigene expression system and its application for coexpression of type I and type II interferons.MicrobiologyOpen · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Bombyx mori nucleopolyhedrovirus (BmNPV) baculovirus expression system (BES) is a eukaryotic expression system. It possesses great capability for post-translation modification in expression of foreign proteins. With the counterselection cassette rpsL-neo and phage λ-Red recombinase, the defective-rescue BmNPV BES reBmBac can be employed for efficient heterologous multigene coexpression at different gene sites in one baculovirus genome. In the present study, a recombinant baculovirus, reBm-Cαγ, carrying two types of chicken interferon (IFN) genes (chIFN-α and chIFN-γ) was constructed using the reBmBac system. The chIFN-α and chIFN-γ genes were inserted into the same baculovirus genome at the polyhedron and p10 gene sites, respectively. The recombinant baculovirus was capable of coexpressing both chIFN-α and chIFN-γ. The expression levels of the two types of IFN in the coexpression product were exponentially high, at approximately 1.7 and 2.5 times higher, respectively, than those in the corresponding single-expression products. The increase in expression level corresponds to replacement of the nonessential p10 gene in the reBm-Cαγ recombinant baculovirus. This coexpression of recombinant chicken IFNs showed superior antiviral activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.